SLU-PP Oral (500 mg)

Pan-ERR Agonist (Oral Research Compound)

SLU-PP Oral (500 mg) is a research-grade formulation consistent with the orally active SLU-PP-332 class pan–estrogen-related receptor (ERR) agonists. Compounds in this class have been studied for their ability to activate ERRα, ERRβ and ERRγ, key nuclear receptors that regulate mitochondrial biogenesis, oxidative metabolism, lipid utilization, thermogenesis, and exercise-like transcriptional programs.

Unlike earlier ERR agonists with limited bioavailability, SLU-PP-332 derivatives have demonstrated oral activity in multiple in vivo models, producing systemic mitochondrial and metabolic effects after oral administration.

Specifications

• Synonyms: SLU-PP, SLU-PP-332 class agonist, pan-ERR oral agonist

• Class: Nuclear receptor agonist / Mitochondrial metabolism modulator

• Route of research administration: Oral (gavage or dietary admixture in animal models)

• Primary targets: ERRα, ERRβ, ERRγ

• Research fields:

  • Mitochondrial biogenesis

  • Exercise mimetics

  • Obesity & metabolic disease

  • Heart failure & organ mitochondrial dysfunction

Mechanism of Action — Pan-ERR Activation (Oral Delivery)

Following oral administration, SLU-PP-type compounds show measurable:

• Systemic plasma exposure with sustained ERR agonism in metabolic tissues

• Uptake in liver, skeletal muscle, heart, and brown adipose tissue

• Activation of ERR target genes, including those regulated by PGC-1α

ERR activation via orally delivered SLU-PP compounds has been shown to:

• Increase transcription of mitochondrial biogenesis genes (TFAM, NRF-1)

• Upregulate oxidative phosphorylation complexes (ETC I–V)

• Enhance fatty-acid uptake and β-oxidation

• Increase mitochondrial oxygen-consumption rate

• Promote genomic programs resembling endurance training

These findings support the use of oral SLU-PP formulations as exercise-mimetic research tools.

SLU-PP Oral in Metabolic Syndrome Research

Orally administered SLU-PP-332 in mice resulted in:

• Reduced obesity and white adipose tissue mass

• Increased whole-body energy expenditure

• Improved insulin sensitivity and glucose metabolism

• Elevated fatty-acid oxidation in liver and skeletal muscle

• Restoration of mitochondrial gene networks suppressed by high-fat diets

These effects were observed in multiple metabolic tissues following repeated oral dosing.

SLU-PP Oral in Mitochondrial Dysfunction & Heart Research

Studies involving oral ERR agonists have shown:

• Improved cardiac mitochondrial respiration

• Reduced cardiac fibrosis and remodeling in heart-failure models

• Increased survival and improved ejection fraction

• Restoration of mitochondrial gene programs involved in ATP production and fatty acid oxidation

These effects highlight the utility of oral SLU-PP derivatives for investigating organ-level mitochondrial restoration.

Exercise-Mimetic Research Applications (Oral Dosing)

Oral ERR agonism produces molecular signatures similar to endurance training:

• Increased oxidative-metabolism genes in skeletal muscle

• Enhanced mitochondrial density and respiratory capacity

• Improved fatigue resistance in animal models

• Upregulation of PGC-1α–dependent pathways

These properties make SLU-PP Oral valuable for studying pharmacologic “exercise-mimetic” mechanisms.

Research Use Only – Important Notice

This SLU-PP Oral (500 mg) product is supplied exclusively for laboratory research:

• Not for human or veterinary use

• Not for diagnostic, therapeutic or cosmetic application

• Intended only for controlled in vivo studies and mechanistic research

• All descriptions summarize preclinical findings and must not be interpreted as medical claims

References

1. Billon C. et al. A synthetic pan-ERR agonist alleviates metabolic syndrome in vivo.
https://pubmed.ncbi.nlm.nih.gov/37739806/

2. Tocris Bioscience. SLU-PP-332 pan-ERR agonist research datasheet.
https://www.tocris.com/products/slu-pp-332_8112

3. Eissa ME. SLU-PP-332 and ERRα agonists: mini-review on metabolic regulation and exercise-mimetic properties.
https://ujpronline.com/index.php/journal/article/view/1355/1932

4. Nasri H. et al. SLU-PP-332: mitochondrial modulatory effects and emerging applications.
https://www.jrenendo.com/PDF/jre-10-e25143.pdf

5. Circulation Journal. Pan-ERR agonism ameliorates heart failure by restoring mitochondrial function.
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.066542

6. Sharma et al. ERR agonists reverse mitochondrial dysfunction and inflammation in aged kidney tissue.
https://www.nature.com/articles/s41598-020-64986-9